China Botanic Hosts Symposium on Research of Polysaccharide Peptide and Natural Innovative Drugs
HARBIN, China, Sept. 27, 2011 /PRNewswire-Asia/ — China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM”) in China, today announced that on September 17, 2011, the Company hosted the National Marine and Terrestrial Symposium on Research and Development of Polysaccharide, Peptide and Natural Innovative Drugs (the “Symposium”) in Harbin, China.
The Symposium was jointly organized by China’s Biochemistry and Molecular Biology Association, and China’s Pharmaceutical Association’s professional committee on biochemical drugs. The symposium was hosted by China Botanic, providing a platform for discussion and exchange of latest research on biological polysaccharides, peptides and natural innovative drugs. Polysaccharides and peptides are biological active substances widely distributed in the oceans and on land, and modern biotechnology is the key technology to the development of natural innovative drugs.
Over 130 academicians, professors, researchers, doctors and other experts from across the country participated in the Symposium. Over 20 scientific experts presented research reports on topics ranging from latest developments on polysaccharides and peptides to their applications. In addition, several experts discussed the physiological basis for anti-fatigue, nerve regulation and combating depression properties of Siberian Ginseng (Acanthopanax) as well as their pharmacological effects. After reviewing the research papers submitted at the Symposium, the leading research scientists concluded that Siberian ginseng (Acanthopanax) polysaccharide likely provides benefits including nerve regulation, immune regulation, anti-tumor effects, resistance to oxidative damage, anti-fatigue effect, anti-bacterial properties, anti-virus, anti-aging and promoting nucleic acid metabolism and phagocytosis for the liver and spleen tissue. The Company’s patented process to extract the effective parts of Siberian Ginseng, and the beneficial pharmacological effects of the Company’s Lyophilized Syringin Powder and Total Flavonoids capsules produced by means of the process also received significant favorable recognition.
“At China Botanic, we believe research and development is the cornerstone for our industry and we are pleased to play a role in organizing and hosting the symposium on research and development of polysaccharide peptide and natural innovative drugs,” said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. “We are encouraged that research continues to further prove the several positive benefits of Siberian Ginseng, which is a key ingredient of our leading Siberian ginseng series. We hope to continue to deliver a growing range of all-natural plant based remedies which benefits our customers and our community.”
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management‘s beliefs, assumptions and expectations of the Company‘s future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company‘s ability to manage expansion of its operations effectively, and other factors detailed in the Company‘s annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
Company Contact: CCG Investor Relations: China Botanic Mr. Mark Collinson, Pharmaceutical Inc. Partner Ms. Portia Tan, IR Phone: +1-310-954-1343 Contact (Los Angeles) Email: Tel: 86-451-8260-2162 firstname.lastname@example.org Email: email@example.com Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: firstname.lastname@example.org
SOURCE China Botanic Pharmaceutical Inc.